Treatment Options From 5 Experts on Neoadjuvant and Adjuvant Therapy for HER2-Positive Early Breast Cancer: An Online Tool

Frankie Ann Holmes, MD, FACP
Sara Hurvitz, MD, FACP
Joyce O'Shaughnessy, MD
Mark D. Pegram, MD
Denise A. Yardley, MD
Released: March 19, 2019
Back Next

References

  1. Cain H, Macpherson IR, Beresford M, et al. Neoadjuvant therapy in early breast cancer: treatment considerations and common debates in practice. Clin Oncol. 2017;29:642-652.
  2. Denduluri N, Chavez-Macgregor M, Telli ML, et al. Selection of optimal adjuvant chemotherapy and targeted therapy for early breast cancer: ASCO Clinical Practice Guideline Focused Update. J Clin Oncol. 2018;36:2433-2443.
  3. Giuliano AE, Connolly JL, Edge SB, et al. Breast cancer-major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67:290-303.
  4. American Joint Committee on Cancer. Breast. In: Edge SB, Byrd DR, Compton CC, et al, editors: AJCC Cancer Staging Manual, 7th edition. New York, NY: Springer; 2010. p 347-376.
  5. Curigliano G, Burstein HJ, Winer EP, et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol. 2019;[Epub ahead of print].
  6. Exman P, Burstein HJ. How old is too old? Breast cancer treatment in octogenarians. 2018;25:1458-1460.
  7. Barcenas CH, Niu J, Zhang N, et al. Risk of hospitalization according to chemotherapy regimen in early-stage breast cancer. J Clin Oncol. 2014;32:1-10.
  8. Denegri A, Moccetti T, Moccetti M, et al. Cardiac toxicity of trastuzumab in elderly patients with breast cancer. J Geriatr Cardiol. 2016;13:355-363.
  9. Sun J, Chia S. Adjuvant chemotherapy and HER-2-directed therapy for early-stage breast cancer in the elderly. Br J Cancer. 2017;116:4-9.
  10. Brollo J, Curigliano G, Disalvatore D, et al. Adjuvant trastuzumab in elderly with HER-2 positive breast cancer: a systematic review of randomized controlled trials. Cancer Treat Rev. 2013;39:44-50.
  11. Cameron D, Piccart-Gebhart MJ, Gelber RD, et al. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet. 2017;389:1195-1205.
  12. Tolaney SM, Barry WT, Dang CT, et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med. 2015;372:134-141.
  13. von Minckwitz G, Procter M, de Azambuja E, et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med. 2017;377:122-131.
  14. Chan A, Delaloge S, Holmes FA, et al. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2016;17:367-377.
  15. Hurvitz S, Chan A, Iannott N, et al. Effects of adding budesonide or colestipol to loperamide prophylaxis on neratinib-associated diarrhea in patients with HER2+ early-stage breast cancer: the CONTROL trial. Program and abstracts of the 2017 San Antonio Breast Cancer Symposium; December 5-9, 2017; San Antonio, Texas. Abstract P3-14-01.
  16. Lipton A. Theriault RL, Hortobagyi G, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long-term follow-up of two randomized, placebo-controlled trials. Cancer. 2000;88:1082-1090.
  17. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet. 2015;386:1353-1361.
  18. Von Moos R, Body JJ, Rider A, et al. Bone-targeted agent treatment patterns and the impact of bone metastases on patients with advanced breast cancer in real-world practice in six European countries. J Bone Oncol. 2017;11:1-9.
  19. Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010;28:5132-5139.
  20. Mando P, Rizzo M, de la Puente CP, et al. High histologic grade and high Ki-67 expression predict phenotypic alterations in node metastasis in primary breast cancers. J Breast Cancer. 2017;20:170-175.
  21. Tao M, Chen S, Zhang X, Zhou Q. Ki-67 labeling index is a predictive marker for a pathological complete response to neoadjuvant chemotherapy in breast cancer: a meta-analysis. Medicine (Baltimore). 2017;96:e9384.
  22. Poulakaki N, Makris GM, Papanota AM, et al. Ki-67 expression as a factor predicting recurrence of ductal carcinoma in situ of the breast: a systematic review and meta-analysis. Clin Breast Cancer. 2018;18:157-167.
Back Next

Disclaimer

Disclaimer: Access to and use of this Interactive Decision Support Tool titled, “Treatment Options From 5 Experts on Neoadjuvant and Adjuvant Therapy for HER2-Positive Early Breast Cancer,” is provided subject to the following terms and conditions. PLEASE READ THESE TERMS CAREFULLY.

The “Treatment Options From 5 Experts on Neoadjuvant and Adjuvant Therapy for HER2-Positive Early Breast Cancer” Interactive Decision Support Tool is designed to educate patients on optimal regimens for HER2+ early breast cancer, based on specific patient and disease characteristics. The information provided is based on the expert guidance of breast cancer experts Frankie Ann Holmes, MD, FACP; Sara Hurvitz, MD, FACP; Joyce O’Shaughnessy, MD; Mark D. Pegram, MD; and Denise A. Yardley, MD.

Although the information contained in the “Treatment Options From 5 Experts on Neoadjuvant and Adjuvant Therapy for HER2-Positive Early Breast Cancer” Interactive Decision Support Tool has been produced and processed from sources believed to be reliable, no warranty, expressed or implied, is made regarding the accuracy, adequacy, completeness, legality, reliability, or usefulness of any information. Patients should always discuss their healthcare decisions with their oncology care team. This disclaimer applies to both the isolated and aggregate uses of the information. Clinical Care Options provides this information on an as-is basis. This disclaimer applies to all data on the Clinical Care Options Web site including but not limited to medical information or opinions. All warranties of any kind, expressed or implied, including but not limited to the implied warranties of merchantability, fitness for a particular purpose, freedom from contamination by computer viruses, and noninfringement of proprietary rights are disclaimed.

Any trademarks are the property of respective companies.

© 2019 Clinical Care Options, LLC. All rights reserved.

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
PIM Logo

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Grace Logo
This activity is supported by an educational grant from
Genentech

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings